CXCL5 anticorps (PE)

N° du produit ABIN2662704

Détail du produit anti-CXCL5 anticorps (PE)

Antigène: CXCL5 (Chemokine (C-X-C Motif) Ligand 5 (CXCL5))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp CXCL5 est conjugé à/à la PE

Application: Flow Cytometry (FACS)

Purification: The antibody was purified by affinity chromatography and conjugated with PE under optimal conditions. The solution is free of unconjugated PE and unconjugated antibody.

Clone: J111B7

Isotype: IgG2b kappa

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide and 0.2 % (w/v) BSA .

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Protect from prolonged exposure to light. Do not freeze.

Stock: 4 °C

Stockage commentaire: The antibody solution should be stored undiluted between 2°C and 8°C.

Détails sur CXCL5

Antigène: CXCL5 (Chemokine (C-X-C Motif) Ligand 5 (CXCL5))

Autre désignation: CXCL5 (CXCL5 Produits)

Synonymes: anticorps ENA-78, anticorps SCYB5, anticorps Cxcl6, anticorps CXCL5, anticorps GCP-2, anticorps GCP2, anticorps SCYB6, anticorps AMCF-II, anticorps LIX, anticorps Scyb5, anticorps Scyb6, anticorps C-X-C motif chemokine ligand 5, anticorps C-X-C motif chemokine ligand 6, anticorps chemokine (C-X-C motif) ligand 5, anticorps C-X-C motif chemokine 5, anticorps CXCL5, anticorps Cxcl6, anticorps LOC701946, anticorps LOC703222, anticorps Cxcl5

Sujet: CXCL5, also known as ENA-78, is a 11.9 kD chemokine and belongs to the intercrine alpha, CXC chemokine family. It is expressed by monocytes and eosinophils in response to IL-1 and TNFα. CXCL5 can interact with CXCR2 and activate neutrophils and induce their migration. In vitro neutrophil chemotactic activity of CXCL5 is three fold higher. IFNγ suppresses expression of CXCL5. NFκB alone is sufficient to induce CXCL5 in contrast to IL-8, which requires both NFκB and C/EBP. Two forms are produced by N terminal proteolytic cleavage, ENA78 (8-78) and ENA 78 (9-78), and these isoforms exhibit higher chemotactic activity. Increased intra-hepatic levels of CXCL5 have been reported in patients with chronic liver disease.

Pathways: Cellular Response to Molecule of Bacterial Origin, Regulation of Leukocyte Mediated Immunity